Anti‐ CD38 therapy in immune thrombocytopenia ( ITP )
British Journal of Haematology · 2026-07 · 209 (1) · 28-30
DOI: 10.1111/bjh.70493 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 23.04.2026. Verfasst von Waleed Ghanima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haemato-Oncology and Research, Østfold Hospital, Grålum, Norway. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Anti‐CD38 monoclonal antibodies have demonstrated rapid responses in immune thrombocytopenia, with response rates across several agents ranging from moderate to high. However, the durability of these responses after treatment discontinuation appears to vary. The therapeutic effects of anti‐CD38 antibodies likely extend beyond depletion of CD38 + plasma cells and may involve broader modulation of the immune system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haemato-Oncology and Research, Østfold Hospital, Grålum, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Qilu Hospital of Shandong University, Shandong University, Jinan, China.
Zitieren
APA
Ghanima, W., & Hou, Y. (2026). Anti‐ CD38 therapy in immune thrombocytopenia ( ITP ). British Journal of Haematology, 209(1), 28-30. https://doi.org/10.1111/bjh.70493
Vancouver
Ghanima W, Hou Y. Anti‐ CD38 therapy in immune thrombocytopenia ( ITP ). British Journal of Haematology. 2026;209(1):28-30. doi:10.1111/bjh.70493
BibTeX
@article{Ghanima2026,
author = {Ghanima, Waleed and Hou, Yu},
title = {Anti‐ CD38 therapy in immune thrombocytopenia ( ITP )},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {1},
pages = {28--30},
doi = {10.1111/bjh.70493}
}
EUVIMED